🧠 Project LUCID

🔬 What is Project LUCID?

Project LUCID is developing the first sublingual esketamine film designed specifically for PTSD treatment. It delivers rapid, sub-dissociative relief with a home-use dosing model and a built-in digital safety + monitoring platform.

💡 Why It Matters

• 12M+ U.S. adults live with PTSD

• No FDA-approved rapid-acting therapies

• Existing SSRIs are slow, often ineffective

• Spravato® is TRD-only and clinic-bound

💊 Our Approach

• 50 mg sublingual film, 3×/week

• Sub-dissociative exposure (~12–15 mg systemic)

• At-home use after first supervised dose

• Digital platform tracks vitals + symptoms

• Target bioavailability: 25–30% in 5–10 min

🧪 Clinical Trial

• Phase 1/2 safety & feasibility pilot (N=12–15)

• First dose in clinic, remainder via telehealth

• CenExel as CRO

• Primary endpoint: CAPS-5/PTSD symptom reduction

🛡 IP Position

• Provisional patent filed April 5, 2025

• Claims: PTSD-only indication, 3×/week dosing, sublingual format, digital integration

• Clear FTO: distinct from Spravato®, Synergistic, Klaria

💰 Seed Round

Now raising $1.5M seed at $6M pre-money valuation
Use of funds: GMP manufacturing, Phase 1/2 trial, platform dev